JP2022528721A5 - - Google Patents
Info
- Publication number
- JP2022528721A5 JP2022528721A5 JP2021559904A JP2021559904A JP2022528721A5 JP 2022528721 A5 JP2022528721 A5 JP 2022528721A5 JP 2021559904 A JP2021559904 A JP 2021559904A JP 2021559904 A JP2021559904 A JP 2021559904A JP 2022528721 A5 JP2022528721 A5 JP 2022528721A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- sequence
- chain complementarity
- determination regions
- complementarity determination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831713P | 2019-04-09 | 2019-04-09 | |
| US62/831,713 | 2019-04-09 | ||
| PCT/US2020/027498 WO2020210512A1 (en) | 2019-04-09 | 2020-04-09 | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528721A JP2022528721A (ja) | 2022-06-15 |
| JP2022528721A5 true JP2022528721A5 (https=) | 2023-04-17 |
| JP7560476B2 JP7560476B2 (ja) | 2024-10-02 |
Family
ID=72748720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559904A Active JP7560476B2 (ja) | 2019-04-09 | 2020-04-09 | キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11180561B2 (https=) |
| EP (1) | EP3952999A4 (https=) |
| JP (1) | JP7560476B2 (https=) |
| KR (1) | KR20210150506A (https=) |
| CN (1) | CN114040800B (https=) |
| AU (1) | AU2020272939A1 (https=) |
| BR (1) | BR112021019128A2 (https=) |
| CA (1) | CA3136625A1 (https=) |
| IL (1) | IL287044A (https=) |
| MX (1) | MX2021012171A (https=) |
| SG (1) | SG11202110610VA (https=) |
| WO (1) | WO2020210512A1 (https=) |
| ZA (1) | ZA202107414B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021004553A2 (pt) | 2018-09-17 | 2021-06-08 | Abcuro, Inc. | anticorpos anti-klrg1 |
| WO2022056289A1 (en) * | 2020-09-11 | 2022-03-17 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| WO2022204529A1 (en) * | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| CA3212311A1 (en) * | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2023009498A1 (en) * | 2021-07-26 | 2023-02-02 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
| WO2024072872A2 (en) * | 2022-09-27 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
| WO2026072990A1 (en) | 2024-09-27 | 2026-04-02 | Abcuro, Inc. | Methods of treating t-cell large granular lymphocytic leukemia |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| AU2001245838A1 (en) | 2000-03-17 | 2001-10-03 | Gemini Science, Inc. | Soluble mast cell function associated antigen (mafa) pharmaceutical compositionsand methods of making and using them |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| JP3536039B2 (ja) * | 2001-05-08 | 2004-06-07 | 独立行政法人 科学技術振興機構 | Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ |
| GB0114107D0 (en) * | 2001-06-09 | 2001-08-01 | Medical Res Council | Respiratory syncytial virus |
| CN101668773B (zh) * | 2007-03-14 | 2016-08-31 | 亚力史制药公司 | 人工程化抗b因子抗体 |
| DK3622815T3 (da) | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| JP2012025694A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| BR112014024023A2 (pt) * | 2012-03-28 | 2017-07-18 | Genentech Inc | anticorpos idiotípicos anti-hcmv e usos dos mesmos |
| WO2016013672A1 (ja) * | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | メモリーインバリアントｎｋｔ細胞マーカー |
| JP7039468B2 (ja) * | 2015-11-17 | 2022-03-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 神経およびその他の障害の処置のための結合アゴニスト |
| BR112018068103A2 (pt) * | 2016-03-08 | 2019-01-15 | Janssen Biotech Inc | anticorpos gitr, métodos e usos |
| JP2019518791A (ja) * | 2016-06-03 | 2019-07-04 | ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ | Ｋｌｒｇ１シグナリングセラピー |
| AU2017326003A1 (en) * | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| WO2019169229A1 (en) * | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
-
2020
- 2020-04-09 AU AU2020272939A patent/AU2020272939A1/en active Pending
- 2020-04-09 BR BR112021019128A patent/BR112021019128A2/pt unknown
- 2020-04-09 SG SG11202110610VA patent/SG11202110610VA/en unknown
- 2020-04-09 CN CN202080036935.9A patent/CN114040800B/zh active Active
- 2020-04-09 JP JP2021559904A patent/JP7560476B2/ja active Active
- 2020-04-09 CA CA3136625A patent/CA3136625A1/en active Pending
- 2020-04-09 KR KR1020217036417A patent/KR20210150506A/ko active Pending
- 2020-04-09 EP EP20788331.5A patent/EP3952999A4/en active Pending
- 2020-04-09 WO PCT/US2020/027498 patent/WO2020210512A1/en not_active Ceased
- 2020-04-09 US US16/844,747 patent/US11180561B2/en active Active
- 2020-04-09 MX MX2021012171A patent/MX2021012171A/es unknown
-
2021
- 2021-10-01 ZA ZA2021/07414A patent/ZA202107414B/en unknown
- 2021-10-06 IL IL287044A patent/IL287044A/en unknown
- 2021-10-20 US US17/506,313 patent/US12139541B2/en active Active
-
2024
- 2024-09-12 US US18/883,109 patent/US20250101114A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022528721A5 (https=) | ||
| RU2563830C2 (ru) | Лечение остеоартрита и боли | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2021527431A5 (https=) | ||
| US11639388B2 (en) | CD3 antigen binding fragment and application thereof | |
| KR102022734B1 (ko) | 신규 조절제 및 용법 | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| JP2021534096A5 (https=) | ||
| JP2018502062A (ja) | Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体 | |
| CA2957491A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| JP2017536341A5 (https=) | ||
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| JP2018510617A5 (https=) | ||
| US20230192861A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| JP2022524588A5 (https=) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| US12146000B2 (en) | Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer | |
| RU2022108410A (ru) | Терапевтические антитела против лиганда cd40 | |
| JP2020519579A (ja) | Ｌｒｒｃ３３阻害剤およびその使用 | |
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| WO2020173378A1 (zh) | 结合人lag-3的抗体、其制备方法和用途 | |
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP7604401B2 (ja) | 抗体および使用方法 | |
| KR20220119393A (ko) | 약학 조성물, 이의 제조 방법 및 이의 용도 | |
| JP2021512652A5 (https=) |